Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710860 | 0.86 | TMPRSS2 (0.38) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16698763 | 0.86 | TMPRSS2 (0.40) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26239498 | 0.84 | LCK (0.33) | TMPRSS2LCKKDRMAPK1 | |
| SCHEMBL26823411 | 0.82 | TMPRSS2 (0.35) | TMPRSS2LCKKDR | |
| SCHEMBL26235345 | 0.80 | LCK (0.35) | TMPRSS2LCKKDRMAPK1 | |
| SCHEMBL26237130 | 0.77 | MAOB (0.31) | TMPRSS2LCKKDRMAPK1 | |
| SCHEMBL16708535 | 0.77 | PI4KA (0.39) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26823086 | 0.77 | TMPRSS2 (0.40) | TMPRSS2LCKKDRMAPK1 | |
| SCHEMBL19779236 | 0.76 | CYP3A4 (0.34) | TMPRSS2 | |
| SCHEMBL16710454 | 0.76 | PI4KA (0.47) | TMPRSS2PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | TMPRSS2 553/4885LCK 2502/4885KDR 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.